Format

Send to

Choose Destination
Blood. 2019 Sep 16. pii: blood.2019000725. doi: 10.1182/blood.2019000725. [Epub ahead of print]

How I treat Waldenström's Macroglobulinemia.

Author information

1
National and Kapodistrian University of Athens, Greece mdimop@med.uoa.gr.
2
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece.

Abstract

Waldenström's macroglobulinemia (WM) is an uncommon lymphoma characterized by the infiltration of the bone marrow by clonal lymphoplasmacytic cells that produce monoclonal IgM. The disease may have an asymptomatic phase or patients may present with symptoms and complications due to marrow or other tissue infiltration or due to physicochemical or immunological properties of the monoclonal IgM. Diagnosis of WM has been clearly defined and genetic testing for somatic mutation of MYD88L265P is a useful tool for the deferential diagnosis from other conditions and specific criteria that define symptomatic disease that needs treatment offer clinical guidance. The treatment of WM has evolved rapidly, with treatment options that include anti-CD20 monoclonal antibody-based combinations and BTK inhibitors. The choice of therapy is based on the need for a rapid disease control, presence of specific disease complications and patient's age. With the use of BTK inhibitors, the use of continuous therapy has been introduced as another option over fixed duration therapy. In this review we will focus on different clinical scenarios and discuss treatment options, based on the available data.

PMID:
31527073
DOI:
10.1182/blood.2019000725

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center